Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,501–1,600 of 3,636
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Ferri, N., Greco, M. F., Corsini, A., & Ruscica, M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa063 · Cited by 11
Improving the Design of Future PCI Trials for Stable Coronary Artery Disease
Marquis‐Gravel, G., Moliterno, D. J., Francis, D. P., Jüni, P., Rosenberg, Y., Claessen, B. E. P. M., Mentz, R. J., Mehran, R., Cutlip, D. E., Chauhan, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.060 · Cited by 10
Self-citationTomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Pavía-López, A. A., Alcocer-Gamba, M. A., Ruiz-Gastélum, E. D., Mayorga-Butrón, J. L., Mehta, R., Díaz-Aragón, F. A., Aldrete-Velasco, J. A., López-Juárez, N., Cruz-Bautista, I., Chávez-Mendoza, A., et al. (2022) · Archivos de cardiología de México · doi:10.24875/acm.m22000081 · Cited by 57
Huang, Y.-C., Chang, C., Tsai, Y., Weng, H., Lin, L.-C., & Lee, J.-D. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060068 · Cited by 9
Parikh, R. R., Breve, F., Magnusson, P., Behzadi, P., & Pergolizzi, J. V. (2022) · Cureus · doi:10.7759/cureus.25641 · Cited by 10
“The ODYSSEY trial [11] also entailed a major CV outcomes study that investigated the long-term effects of alirocumab on LDL-C reduction, and their association with CV events in a patient population of 18,924 with a history of recent acute coronary syndrome episodes within the previous year.”
BackgroundKudo, T., Sasaki, K., & Tada, H. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.010 · Cited by 9
Knöchel, J., Nilsson, C. A. M., Carlsson, B., Wernevik, L. C., Hofherr, A., Gennemark, P., Jansson‐Löfmark, R., Isaksson, R., Rydén‐Bergsten, T., Hamrén, B., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12866 · Cited by 9
Lipid management to mitigate poorer postkidney transplant outcomes
Skulratanasak, P., & Larpparisuth, N. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000841 · Cited by 10
“Humanized monoclonal antibody (mAb) to PCSK9 consisting of alirocumab (IgG1mAb) and evolocumab (IgG2mAb) provide a reduction in plasma LDL-C levels by 60% and subsequently a lower risk of acute myocardial infarction, stroke, and all-cause mortality [46,47].”
BackgroundNakahara, T., Strausś, H. W., Narula, J., & Jinzaki, M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.08.009 · Cited by 13
Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?
Liuzzo, G., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad241 · Cited by 9
Lipoprotein(a): a Case for Universal Screening in Youth
Alankar, A., Brar, P. C., & Kohn, B. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01120-3 · Cited by 10
Karalis, D. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000896 · Cited by 9
Ogungbe, O., Grant, J. K., Ayoola, A., Bansah, E. C., Miller, H., Plante, T. B., Sheikhattari, P., Commodore-Mensah, Y. Y., Turkson‐Ocran, R., Juraschek, S. P., et al. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01942-2 · Cited by 10
PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
Bodapati, A. P., Hanif, A., Okafor, D. K., Katyal, G., Kaur, G., Ashraf, H., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.46605 · Cited by 21
“When used with the maximum tolerable dose of statin treatment, evolocumab mitigated the risk of CV events in individuals with ASCVD [8].”
BackgroundInfluentialAnagnostis, P. G., Antza, C., Florentin, M., & Kotsis, V. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97845 · Cited by 13
“The monoclonal antibodies alirocumab and evolocumab have been consistently shown to induce robust reductions in LDL-C levels by simultaneously achieving a significant decrease in cardiovascular events [53, 54].”
BackgroundApple, S. J., Clark, R. E., Daich, J., González, M. L., Ostfeld, R. J., Toth, P. P., Bittner, V., Martin, S. S., Rana, J. S., Nasir, K., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412350 · Cited by 13
“…(non-HDL-C) > 100 mg/dL or apoB > 80 mg/dL, illustrated that those in the PCSK9-I group had a lower rate of death from CAD, nonfatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization compared to placebo (9.5% vs 11.1%, HR, 0.85; 95% CI 0.78–0.93; p 0.001) [ 19].”
BackgroundInfluentialSelf-citationInflammation as a New Therapeutic Target among Older Patients with Ischemic Heart Disease
Maidana, D., Arroyo-Álvarez, A., Arenas‐Loriente, A., Barreres-Martín, G., Muñoz-Alfonso, C., Bompart, D., Claramunt, F. E., del Burgo, R. B., Guillén, P. L. C., García‐Blas, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020363 · Cited by 10
“However, further exploration is required to fully elucidate the extent and significance of their anti-inflammatory effects [48].”
BackgroundMackinnon, E. S., Leiter, L. A., Wani, R. J., Burke, N., Shaw, E., Witges, K., & Goodman, S. G. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00349-6 · Cited by 10
“Evidence contributing to this recommendation includes CV outcome clinical trials with non-statin therapies such as ezetimibe (IMPROVE-IT) [21] and PCSK9is (FOURIER [4, 6, 22] and ODYSSEY OUTCOMES [5, 23]).”
Self-citationAlanezi, M., Yan, A. T.-K., Tan, M., Bourgeois, R. L., Malek-Marzban, P., Beharry, R., Al-Kurtass, S., Gyenes, G. T., Nadeau, P.-L., Nwadiaro, N. F., et al. (2024) · Cardiology · doi:10.1159/000536392 · Cited by 9
“…trial, the population included patients aged > 18 years who were treated for ACS within 1 – 12 months prior to enrolment and had an LDL-C ≥ 1.81 mmol/L (70 mg/dL) despite maximally tolerated statin with or without ezetimibe therapy, including patients who were intolerant of ≥ 2 statins [11].”
BackgroundMethodInfluentialSelf-citationLucà, F., Pavan, D., Gulizia, M. M., Manes, M. T., Abrignani, M. G., Benedetto, F. A., Bisceglia, I., Brigido, S., Caldarola, P., Calvanese, R., et al. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae034 · Cited by 11
Wright, J., & Subramanian, S. (2024) · The Medical clinics of North America · doi:10.1016/j.mcna.2024.03.005 · Cited by 9
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis
Huang, C., Wang, S., Fan, F. S., Lu, H., & Wei, J. C. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae056 · Cited by 10
New agents to reduce cholesterol levels: implications for nephrologists
Vecchio, L. D., Baragetti, I., & Locatelli, F. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz013 · Cited by 9
Guedeney, P., Claessen, B. E. P. M., Baber, U., Camaj, A., Sorrentino, S., Aquino, M. B., Blum, M., Chandiramani, R., Goel, R., Elsayed, S., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.03.005 · Cited by 10
Chao, T., Hsiao, P., Liu, M.-E., Wu, C.-J., Chiang, F., Chen, Z., Chen, C.-P., Yeh, H., Lee, T.-H., & Chiang, C. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000062 · Cited by 7
Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging
Iwai, T., Kataoka, Y., Otsuka, F., Asaumi, Y., Nicholls, S. J., Noguchi, T., & Yasuda, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1676150 · Cited by 10
“Recent clinical trial reported a significant reduction of ASCVD under the use of proprotein convertase subtilisin/kexin type 9 inhibitor in subjects with CKD [67,68].”
BackgroundOren, O., Kludtke, E. L., & Kopecky, S. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.016 · Cited by 9
Robinson, J. G., Jayanna, M. B., Merz, C. N. B., & Stone, N. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240166 · Cited by 10
Rymer, J. A., Swaminathan, R. V., Aday, A. W., Patel, M. R., & Gutierrez, J. A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01451-0 · Cited by 9
PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer
Patrono, C., & Volpe, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab047 · Cited by 9
Aranzulla, T. C., Piazza, S., Ricotti, A., Musumeci, G., & Gaggiano, A. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29743 · Cited by 11
Chakraborty, A., Pang, J., Chan, D. C., Barnett, W., Woodward, A. M., Vorster, M., & Watts, G. F. (2021) · Clinical Cardiology · doi:10.1002/clc.23607 · Cited by 9
“probably mediates the principal cardiovascular benefits of this treatment.(18,19,28,48,49)”
BackgroundCainzos‐Achirica, M., Anugula, D., Mszar, R., Grandhi, G. R., Patel, K. V., Bittencourt, M. S., Blankstein, R., Blaha, M. J., Blumenthal, R. S., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.09.006 · Cited by 8
Self-citationZhao, X., Song, L., Wang, Y., Li, J., Zhou, J., Chen, R., Liu, C., Zhou, P., Sheng, Z., Chen, Y., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s334246 · Cited by 9
Gu, S. Z., Costopoulos, C., Huang, Y., Bourantas, C. V., Woolf, A. K., Sun, C. J., Teng, Z., Losdat, S., Räber, L., Samady, H., et al. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab039 · Cited by 10
Ahn, J. H., Ahn, Y., Jeong, M. H., Kim, J. H., Hong, Y. J., Sim, D. S., Kim, M. C., Cho, K. H., Hyun, D. Y., Lee, S. H., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.020 · Cited by 13
Ben-Naim, L., Khalaila, I., & Papo, N. (2022) · Protein Engineering Design and Selection · doi:10.1093/protein/gzab032 · Cited by 9
Li, H., Wang, B., Mai, Z., Yu, S., Zhou, Z., Lu, H., Lai, W., Li, Q., Yang, Y., Deng, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.822626 · Cited by 10
Lee, M., George, J., Shahab, H., Hermel, M. H., Rana, J. S., & Virani, S. S. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00985-0 · Cited by 9
Abe, S., Haruyama, Y., Kobashi, G., Toyoda, S., Inoue, T., Tomiyama, H., Ishizu, T., Kohro, T., Higashi, Y., Takase, B., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1068 · Cited by 10
Masson, W. M., Corral, P., Barbagelata, L., Cobo, A. L., Nogueira, J. P., Siniawski, D. A., & Ray, K. K. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.004 · Cited by 9
Wolf, S., Spirk, D., Forgó, G., Sebastian, T., Voci, D., Kucher, N., & Barco, S. (2022) · VASA · doi:10.1024/0301-1526/a001025 · Cited by 10
Shen, M., Nargesi, A. A., Nasir, K., Bhatt, D. L., & Khera, R. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026075 · Cited by 9
Self-citationYang, N., Wang, M., Liu, J., Liu, J., Hao, Y., Zhao, D., & on behalf of CCC-ACS Investigators (2022) · Metabolites · doi:10.3390/metabo12100898 · Cited by 9
Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
Santos, R. D., & Rocha, V. Z. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac656 · Cited by 10
de Gaetano, M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101699 · Cited by 9
Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
Piña, P., Lorenzatti, D., Paula, R., Daich, J., Schenone, A. L., Gongora, C. A., Garcia, M. J., Blaha, M. J., Budoff, M. J., Berman, D. S., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100451 · Cited by 12
“The FOURIER [106] and ODYSSEY trials [107] demonstrated in symptomatic patients with established ASCVD that even for patients Fig.”
MethodEpigenetics in cardiovascular health and disease
Chew, N., Loong, S. S. E., & Foo, R. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.01.002 · Cited by 10
Current and future options in cholesterol lowering treatments
Elis, A. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.010 · Cited by 12
Khan, Z. U., Gul, A., Yousif, Y., & Gupta, A. (2023) · Cureus · doi:10.7759/cureus.35463 · Cited by 9
“Similar findings were observed in The FOURIER study that included 27,564 patients with ASCVD and LDL-C ≥ 70 mg/dL receiving statin therapy and had a 15% reduction in the primary outcome following initiation of PCSK9 inhibitor therapy [28,29].”
ResultLi, J. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.06.002 · Cited by 9
“Notably, similar to the well-known PCSK9monoclonal antibodies alirocumab and evolocumab, tafolecimab markedly reduces LDLC concentration approximately 70% accompanied by the reduction in non–high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) levels.(6,7) Those lipid-related markers are highly p…”
BackgroundAlirocumab for low-density Lipoprotein Cholesterol Lowering
Roth, E. M. (2018) · Future Cardiology · doi:10.2217/fca-2018-0072 · Cited by 10
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Nicholls, S. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1103-2 · Cited by 10
Jayanna, M. B., & Robinson, J. G. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13701 · Cited by 10
“benefit was limited to patients with baseline LDL more than 100 mg/dL, even in this high-risk population enrolling patients with recent acute coronary syndrome.(35) This suggests that once there is development of advanced atherosclerotic disease, further reduction in cholesterol levels by drug therapy has diminishing…”
BackgroundBrandts, J., & Müller‐Wieland, D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0802-x · Cited by 10
Poststatin Lipid Therapeutics: A Review
Jia, X., Lorenz, P., & Ballantyne, C. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-32 · Cited by 14
Tratamiento hipolipemiante en la prevención secundaria de la enfermedad cerebrovascular isquémica
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.002 · Cited by 15
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
“The proof-of-concept that the above described LDL-C plasma levels reduction caused by alirocumab would translate into a lower incidence of clinically relevant CV events came from the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial [32, 46…”
BackgroundLipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.07.001 · Cited by 10
Furuhashi, M., Sakuma, I., Morimoto, T., Higashiura, Y., Sakai, A., Matsumoto, M., Sakuma, M., Shimabukuro, M., Nomiyama, T., Arasaki, O., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.58396 · Cited by 11
The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
Kongmalai, T., Chuanchaiyakul, N., Sripatumtong, C., Tansit, T., Srinoulprasert, Y., Klinsukon, N., & Thongtang, N. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01447-3 · Cited by 10
“Second, percent inhibition of PCSK9 mAb at baseline in this study was less than previous report [4, 5] because”
ResultBays, H. E. (2019) · Circulation · doi:10.1161/circulationaha.119.041496 · Cited by 10
Liu, Y., Li, D., Chai, M., Cong, H., Cong, X., Dai, J., Du, R., Gao, M., Guo, J., Guo, Y., et al. (2020) · PubMed · doi:10.11909/j.issn.1671-5411.2021.04.005 · Cited by 11
“[11] ODYSSEY outcomes and FOURIER studies have also shown that PCSK-9 inhibitors can further reduce LDL-C levels, major adverse cardiovascular events (MACE), and improve clinical outcomes.”
MethodPCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
Xiao, Y., Ba, Z., Pang, S., Liu, D., Wang, H., Liang, H., Wang, Y., & Yuan, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311380 · Cited by 12
“Adverse Events (AEs) of PCSK9 inhibitors are infrequent and include inject-site reactions, myalgia, and flu-like symptoms, most of which are mild [13,14,16,17].”
BackgroundResultEloso, J., Awad, A., Zhao, X., Cunningham, F. E., Zhang, R., Dong, D., Kelley, C., Glassman, P. A., & Aspinall, S. L. (2023) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2023.100035 · Cited by 8
Almigbal, T. H., Almunif, D. S., Deshisha, E. A., Altaradi, H. B., Alrasheed, A. A., Batais, M. A., & AlHabib, K. F. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101759 · Cited by 9
“The clinical trials, FOURIER (Evolocumab) (Sabatine et al., 2017) and ODYSSEY OUTCOMES (Alirocumab) (Schwartz et al., 2018) studied PCSK9 inhibitors in a very high-risk population.”
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
Luo, Q., Tang, Z., Wu, P., Chen, Z., Fang, Z., & Luo, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218968 · Cited by 9
Wang, Z., Cheng, Z., Ji, X., Pei, Z., Yang, K., Huang, Z., Wu, Y., Wang, G., Wang, M., Zhao, Y., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.04.011 · Cited by 9
Akiyama, T., Ikegami, R., Kubota, N., Takano, T., Yoneyama, S., Okubo, T., Hoyano, M., Ozaki, K., & Inomata, T. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0242 · Cited by 9
Therapeutic Gene Editing in Dyslipidemias
Zadeh, S. S. T., & Shapiro, M. D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508286 · Cited by 8
“Another human monoclonal antibody is alirocumab which can reduce the risk of CVD events in people with a history of acute coronary syndrome [47].”
BackgroundQuality Assurance for Multiplex Quantitative Clinical Chemistry Proteomics in Large Clinical Trials
Reijnders, E., Romijn, F. P. H. T. M., Arslan, F., Georges, J. J. J., Pieterse, M., Schipper, E. R., Didden-Buitendijk, S., Martherus-Bultman, M. C., Smit, N. P. M., Diederiks, N. M., et al. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae092 · Cited by 8
Self-citationvan der Stouwe, J. G., Godly, K., Kraler, S. C., Godly, J., Matter, C. M., Wenzl, F. A., von Eckardstein, A., Räber, L., Mach, F., Obeid, S. N., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14314 · Cited by 9
“3,8,9 Therefore, BT might represent an important vital sign which could facilitate the identification of patients which may particularly benefit from anti-inflammatory interventions.”
Lin, Y.-C., Lai, T.-S., Chen, Y.-T., Chou, Y.-H., Chen, Y.-M., Hung, K.-Y., & Tu, Y.-K. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.09.037 · Cited by 10
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., & Jawla, S. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.10.001 · Cited by 13
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70039 · Cited by 16
Impact of Sex Differences on Lipids and Statin Utilization
Rodriguez, C. P., Burka, S., & Michos, E. D. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01286-y · Cited by 11
2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease
Williams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.001 · Cited by 15
PCSK9 deficiency promotes the development of peripheral neuropathy
Jaafar, A. K., Paulo-Ramos, A., Rastoldo, G., Veeren, B., Planesse, C., Bringart, M., Rondeau, P., Chemello, K., Meilhac, O., Lambert, G. C., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.183786 · Cited by 11
Li, J., Wang, M., Qu, K., Sun, Y., Yin, Z., Dong, N., Sun, X., Xu, Y., Chen, L., Zhang, S., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.015 · Cited by 9
“PCSK9 inhibitors ( e . g ., alirocumab and evolocumab) are also known to effectively improve LDL-cholesterol levels 54,55 .”
Giovanni, G. D., Fujino, M., Kataoka, Y., Butters, J., Hucko, T., Puri, R., Nissen, S. E., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf211 · Cited by 9
A Critical Appraisal of Lipid Management in the Post-Statin Era
Spitz, J. A., Patel, J., Agarwala, A., Sharma, G. V., Mehta, A., Natarajan, P., Nasir, K., Morris, P. B., Blumenthal, R. S., & Shapiro, M. D. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101823 · Cited by 20
Anumas, S., & Inagi, R. (2025) · Nephrology · doi:10.1111/nep.70098 · Cited by 12
“However, clinical trials evaluating these agents have generally excluded patients with severely impaired kidney function [90–94].”
König, T., Berliner, D., Diekmann, J., Akin, M., Pfeffer, T. J., Martinez, C. S., Garcheva, V., Bengel, F. M., Bauersachs, J. K., & Schäfer, A. (2025) · EuroIntervention · doi:10.4244/eij-d-25-00034 · Cited by 10
Reddin, C., Stankard, A., Chan, K. Y., Krewer, F., Judge, C., Canavan, M., Davis, D. H. J., & O’Donnell, M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf219 · Cited by 8
“Fifteen trials reported dementia or cognitive impairment on follow-up (139 169 participants) [6, 16–21, 32, 33, 24, 34, 25–27].”
Apolipoproteins in Chronic Kidney Disease and Kidney Transplant: A Long Unfinished Story
Secondulfo, C., Izzo, C., Vecchione, N., Minelli, G., Russo, D., Russo, D., Barra, R., Molinaro, G., Apicella, L., Iacuzzo, C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199664 · Cited by 10
“…and alirocumab produced consistent and large LDL-C reductions (roughly 45–55% when added to statin therapy) that translated into significant reductions in major adverse cardiovascular events; these benefits were observed across the range of kidney function represented in those trials [98,102,103].”
Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study
Bellows, B. K., Zhang, Y., Ruiz‐Negrón, N., Kazi, D. S., Khera, A. V., Woo, J. G., Urbina, E. M., Jacobs, D. R., Allen, N. B., Wong, J. B., et al. (2025) · JAMA · doi:10.1001/jama.2025.20648 · Cited by 12
Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage
Polo-Barranco, A., Rebolledo-Maldonado, C., Esquiaqui-Rangel, V., Nuñez-Mejia, A., Rambal-Torres, J., Barraza-Ahumada, V., Vargas-Cantillo, S., la Cruz, W. B.-D., Liñán-Martínez, V., Rada-Obeso, V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311427 · Cited by 9
“…diabetic patients with elevated Lp(a) should be considered for more aggressive lipid-lowering regimens—including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and inclisiran [197–199]—and, in the near future, novel agents specifically targeting Lp(a) [200].”
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
Tsimikas, S., Szarek, M. J., Cobbaert, C. M., Romijn, F. P. H. T. M., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.073855 · Cited by 13
Self-citationDiretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT
Jannink, J., Zelm, A. V., Chemlal, S., Martens, F. M. A. C., Poorthuis, M. H. F., Visseren, F. L. J., Mosterd, A., & Fiolet, A. T. L. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01382-z · Cited by 11
Kini, A. S., Vengrenyuk, Y., Liu, J., Yasumura, K., Revaiah, P. C., Mandava, A., Shah, H., Sweeny, J. M., Khera, S., Kapur, V., et al. (2026) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.12.013 · Cited by 10
Cholesterol-Inflammation Fusion Hypothesis in Atherosclerosis
Zeng, R., Li, S., & Li, J. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.002 · Cited by 13
Frías, J. P., Koren, M. J., Loizeau, V., Merino‐Trigo, A., Louie, M. J., Raudenbush, M. A., & Batsu, I. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.11.008 · Cited by 8
Techorueangwiwat, C., Kanitsoraphan, C., & Hansrivijit, P. (2021) · F1000Research · doi:10.12688/f1000research.28254.1 · Cited by 10
Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8
Tang, X., Liu, L., Yang, J., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02115-1 · Cited by 8
Fonarow, G. C., Kosiborod, M., Rane, P., Nunna, S., Villa, G., Habib, M., Arellano, J., Mues, K. E., Sun, K., & Wade, R. L. (2021) · Clinical Cardiology · doi:10.1002/clc.23706 · Cited by 10
Blumenthal, D. M., Maddox, T. M., Aragam, K. G., Sacks, C. A., Virani, S. S., & Wasfy, J. H. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007237 · Cited by 11
Ng, A. K., Ng, P. Y., Ip, A., & Siu, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760926 · Cited by 9
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

